Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

Nina Shah, MD, a hematologist and oncologist, as well as an associate professor of medicine in the Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel (orva-cel; JCARH125) in relapsed/refractory multiple myeloma.

The EVOLVE study is investigating the CAR T-cell product in patients with relapsed/refractory multiple myeloma. This product is similar to other products in that it targets BCMA, but the way the cells are cultured differs slightly. Some early phase 1 data have demonstrated an overall response rate of 92% with this product, Shah says.

Several doses of the product are being examined in the trial and there is no extensive, long-term follow-up to help determine the duration of response or progression-free survival. Multiple BCMA-targeted CAR T-cell therapies are emerging, which equates to more options for patients with this disease, concludes Shah.